Browsing by Author Yen, CJ

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 10 of 10
TitleAuthor(s)Issue DateViews
 
A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
Journal:Clinical Cancer Research
Yau, TCCLencioni, RSukeepaisarnjaroen, WChao, YYen, CJLausoontornsiri, WChen, PJSanpajit, TCamp, ACox, DSGagnon, RLiu, YRaffensperger, KEKulkarni, DKallender, HOttesen, LHPoon, RTPBottaro, DP
2017
98
 
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Journal:Therapeutic Advances in Medical Oncology
Qin, SChan, SLSukeepaisarnjaroen, WHan, GChoo, SPSriuranpong, VPan, HYau, TGuo, YChen, MRen, ZXu, JYen, CJLin, ZZManenti, LGu, YSun, YTiedt, RHao, LSong, WTanwandee, T
2019
80
 
Clinical and immunologic responses to a B-cell epitope vaccine in patients with HER2/neu-overexpressing advanced gastric cancer—Results from phase Ib trial IMU.ACS.001
Journal:Clinical Cancer Research
Wiedermann, UGarner-Spitzer, EChao, YMaglakelidze, MBulat, IDechaphunkul, AArpornwirat, WCharoentum, CYen, CJYau, TCTanasanvimon, SManeechavakajorn, JSookprasert, ABai, LYChou, WCUngtrakul, TDrinic, MTobias, JZielinski, CCChong, LEde, NJMarino, MTGood, AJ
2021
11
 
A Phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC)
Proceeding/Conference:Journal of Hepatology
Yau, TYen, CJChen, PJChau, YLencioni, RKallender, HOttesen, LHPoon, RTP
2011
218
 
A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC)
Proceeding/Conference:Journal of Clinical Oncology
Yau, TCCSukeepaisarnjaroen, WChao, YYen, CJLausoontornsiri, WChen, PJSanpajit, TLencioni, RCamp, ACCox, DSKallender, HOttesen, LHPoon, RTP
2012
88
 
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma
Journal:Clinical Cancer Research
Lim, HYMerle, PWeiss, KHYau, TCCRoss, PMazzaferro, VBlanc, JFMa, YTYen, CJKocsis, JChoo, SPSukeepaisarnjaroen, WGérolami, RDufour, JFGane, EJRyoo, BYPeck-Radosavljevic, MDao, TYeo, WLamlertthon, WThongsawat, STeufel, MRoth, KReis, DChilds, BHKrissel, HLlovet, JM
2018
50
 
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, Versus Chemotherapy in Patients With Recurrent/Metastatic Nasopharyngeal Cancer
Journal:Clinical Cancer Research
Even, CWang, HMLi, SHNgan, KCRDechaphunkul, AZhang, LYen, CJChan, PCChakrabandhu, SMa, BBYTanasanvimon, SLee, VHFLou, PJLi, ZSpira, AISukari, AGuigay, JMcCune, SGonzalez-Maffe, JSzpakowski, SYao, YLiang, HMataraza, JSéchaud, RManenti, LLim, DWT
2021
25
 
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study
Journal:European Journal of Cancer
Chau, IPeck-Radosavljevic, MBorg, CMalfertheiner, PSeitz, JFPark, JORyoo, BYYen, CJKudo, MPoon, RTPPastorelli, DBlanc, JFChung, HCBaron, ADOkusaka, TBowman, LCui, ZLGirvan, ACAbada, PBYang, LZhu, AX
2017
54
 
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Journal:The Lancet Oncology
Zhu, AXPark, JORyoo, BYYen, CJPoon, RTP
2015
50
 
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma
Journal:Journal of Hepatology
Abou-Alfa, GKPuig, ODaniele, BKudo, MMerle, PPark, JWRoss, PPeron, JMEbert, OChan, SPoon, RTPColombo, MOkusaka, TRyoo, BYMinguez, BTanaka, TOhtomo, TUkrainskyj, SBoisserie, FRutman, OChen, YCXu, CShochat, EJukofsky, LReis, BChen, GDi Laurenzio, LLee, RYen, CJ
2016
74
Showing results 1 to 10 of 10